Avacta Achieves Clinical Proof of Mechanism for AVA6103
LONDON and PHILADELPHIA — September 16, 2026 Avacta Therapeutics announced clinical proof of mechanism for AVA6103, its next-generation controlled-release...
trastuzumab deruxtecan
Advertisement
AstraZeneca and Daiichi Sankyo’s Enhertu Delivers 14.3-Month PFS in HER2-Mutant NSCLC
Seoul, South Korea, September 14, 2026 AstraZeneca and Daiichi Sankyo announced positive results from the Phase III DESTINY-Lung04 trial,...
Daiichi Sankyo and AstraZeneca Report Enhertu Phase 3 Win
Tokyo, Japan — August 17, 2026 Daiichi Sankyo and AstraZeneca announced positive topline results from the DESTINY-Lung04 Phase 3...
Daiichi Sankyo and AstraZeneca Win CHMP Backing for Enhertu in HER2-Positive Breast Cancer
Tokyo, July 24, 2026 Daiichi Sankyo and AstraZeneca announced that the European Medicines Agency’s Committee for Medicinal Products for...
Daiichi Sankyo and AstraZeneca Secure EU Enhertu Approval
TOKYO, June 29, 2026 Daiichi Sankyo and AstraZeneca have announced that the European Commission (EC) has approved Enhertu® (trastuzumab...
Advertisements
Parexel Showcases Oncology Research and Patient-Centered Innovation at ASCO 2026
RALEIGH, N.C. | May 28, 2026 Parexel announced that two oncology-focused research posters have been accepted for presentation at...
AstraZeneca and Daiichi Sankyo Advance Enhertu in Tumour-Agnostic Oncology
Cambridge, United Kingdom – May 22, 2026 AstraZeneca and Daiichi Sankyo announced that the European Medicines Agency’s Committee for...
Daiichi Sankyo Expands ENHERTU Use in Japan
TOKYO, JAPAN, March 23, 2026 Daiichi Sankyo has announced that Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) has approved...
Advertisement
